Bio-Rad (BIO) Q4 2025: Process Chromatography Set for Mid-Teens Decline, Reshaping Segment Mix
Bio-Rad enters 2026 with stabilizing end markets but faces a sharp process chromatography downturn that will reshape its Life Science segment mix. Management’s focus on operational rigor and portfolio optimization is evident, with early traction in digital PCR and diagnostics offset by margin pressure and muted top-line guidance. Investors should watch for execution on cost initiatives and the evolving impact of regulatory and customer shifts in key product lines.
Summary
- Process Chromatography Reset: Segment faces mid-teens decline, altering Life Science growth dynamics.
- Margin Recovery Hinges on Execution: Operational initiatives must offset recent gross margin shortfalls.
- Digital PCR Momentum: QX700 adoption and assay growth underpin long-term core platform confidence.
Business Overview
Bio-Rad Laboratories is a global provider of life science research and clinical diagnostics products. The company generates revenue through two main segments: Life Science (instruments, reagents, and consumables for research and bioprocessing, including digital PCR and process chromatography) and Clinical Diagnostics (quality controls, blood typing, and disease testing products for laboratories and hospitals). Revenue is split between these segments, with Diagnostics slightly larger in recent years. Bio-Rad’s business model relies on instrument sales driving recurring consumables and reagent revenue, supplemented by a broad assay menu and a global customer base.
Performance Analysis
Bio-Rad delivered Q4 results within its revised revenue and operating margin guidance, but gross margin fell short due to execution-related supply chain costs. Diagnostics led growth, with strong quality control and blood typing demand, while Life Science was weighed down by soft academic and biotech funding and a pronounced drop in process chromatography sales. The company’s DDPCR (droplet digital PCR) portfolio, especially the QX700 platform, achieved mid-single-digit growth, reflecting both conversion from QPCR and competitive wins. However, the overall Life Science segment saw a small revenue decline, and process chromatography’s volatility was highlighted as a key driver of quarter-to-quarter lumpiness.
Gross margin compression was driven by expedited freight and service costs arising from a compressed sales cycle due to the U.S. government shutdown, as well as slower-than-expected procurement savings. SG&A expenses increased on higher employee-related costs, while R&D spend normalized after acquisition-related charges in the prior year. Free cash flow improved meaningfully, aided by working capital discipline, and the company maintained a strong cash position despite significant share repurchases earlier in the year.
- Diagnostics Outperformance: Segment growth was broad-based, with quality controls and blood typing leading, offsetting China diabetes reimbursement headwinds.
- Process Chromatography Volatility: Revenue concentration and regulatory shifts triggered a sharp decline, with segment now over-indexed to vaccine-related demand.
- Margin Compression: Elevated supply chain costs and delayed procurement benefits dragged Q4 gross margin below expectations.
Bio-Rad’s core consumables and digital PCR platforms are showing resilience, but near-term performance is constrained by external and executional headwinds, especially in the Life Science segment.
Executive Commentary
"We are executing actions to improve operational performance, expand margins, and focus investments in our most attractive growth platforms. We are confident these actions will translate into improved financial results over time."
John DiVincenzo, President and Chief Operating Officer
"We do remain highly focused on driving long-term value and are already seeing the impact of an intentional performance-related approach. Kind of against the dynamic backdrop of last year, Bio-Rad delivered results that reflect both the challenges of the environment, but also I think the resilience of our business."
Norman Schwartz, Chief Executive Officer
Strategic Positioning
1. Process Chromatography Reset
Process chromatography, purification technology for bioprocessing, is now forecasted to decline mid-teens in 2026, reflecting regulatory changes and customer vaccine production shifts. Management frames this as a short-term reset, with longer-term mid-single-digit growth expected as the clinical pipeline matures and the portfolio broadens beyond current vaccine concentration.
2. Digital PCR Platform Expansion
The QX700 droplet digital PCR platform is gaining traction, with customer adoption driven by both competitive wins and QPCR conversion. The business is underpinned by a large installed base and robust consumables pull-through, supporting management’s confidence in digital PCR as a durable growth pillar and margin lever.
3. Diagnostics Portfolio Strength
Diagnostics returned to growth, led by quality controls and blood typing, with stable reimbursement and no new VBP (volume-based procurement) headwinds in China. Management expects mid-single-digit growth in quality controls and low-single-digit growth in the rest of the portfolio, reflecting a stable but unspectacular demand environment.
4. Operational Discipline and Cost Actions
Bio-Rad is executing on restructuring, procurement, and supply chain initiatives to improve gross margin and SG&A discipline. The company completed its 2025 restructuring, with savings reflected in 2026 guidance, but must deliver on sequential margin improvement as one-time costs abate and efficiency measures ramp.
5. Capital Allocation and M&A Readiness
With $1.5 billion in cash and a pause in Q4 buybacks, management signals readiness for opportunistic M&A to accelerate top-line growth, while maintaining flexibility for further buybacks as conditions warrant.
Key Considerations
Bio-Rad’s 2026 setup is defined by a mix of stabilization and transition, with management betting on operational rigor and innovation to offset external and portfolio-driven headwinds.
Key Considerations:
- Process Chromatography Drag: A mid-teens decline in this high-value segment will dilute Life Science growth and margin mix in the near term.
- Digital PCR Opportunity: QX700 momentum and assay expansion could drive share gains and higher-margin revenue if adoption trends continue.
- Diagnostics as a Stabilizer: Quality controls and blood typing offer steady growth, providing ballast against Life Science volatility.
- Cost Discipline Crucial: Delivering on procurement, manufacturing, and SG&A initiatives is vital to achieving guided margin recovery.
- Capital Deployment Flexibility: A strong balance sheet supports M&A ambitions, but execution risk remains if integration or target selection falters.
Risks
Bio-Rad faces several risks: Process chromatography’s revenue concentration exposes the company to regulatory and customer strategy shifts, amplifying volatility. Margin recovery depends on consistent execution of operational initiatives, and any delays could further pressure profitability. Diagnostics growth remains modest, and a lack of acceleration could limit offset to Life Science headwinds. Finally, capital allocation toward M&A brings integration and strategic fit risks, while external factors (trade, tariffs, funding cycles) add to uncertainty.
Forward Outlook
For Q1 2026, Bio-Rad expects:
- Low single-digit revenue decline YoY, with sequential improvement each quarter.
- Gross margin to increase by 100 basis points from Q4, as one-time costs abate.
For full-year 2026, management guided:
- Currency-neutral revenue growth of 0.5% to 1.5%.
- Life Science segment flat to 0.5% growth, with core Life Science (ex-chromatography) up nearly 4%.
- Process chromatography down mid-teens; diagnostics up 1% to 2%.
- Non-GAAP gross margin of 54% to 54.5% and operating margin of 12% to 12.5%.
- Free cash flow of $375 million to $395 million.
Management emphasized that operational improvements and portfolio optimization will be key to achieving guidance, while capital deployment will remain opportunistic.
- Process chromatography weakness is fully embedded in guidance.
- Sequential margin improvement expected as cost actions take hold.
Takeaways
Bio-Rad’s 2026 outlook is defined by a process chromatography reset, digital PCR momentum, and a renewed focus on operational discipline.
- Process Chromatography Volatility: Segment’s mid-teens decline will pressure Life Science growth and margin mix, requiring offset from other platforms.
- Margin Recovery Path: Execution on procurement, manufacturing, and cost control is critical to restoring profitability levels.
- Platform Growth Watch: Investors should monitor QX700 digital PCR adoption, assay expansion, and diagnostics growth for evidence of portfolio resilience.
Conclusion
Bio-Rad enters 2026 at a strategic crossroads, balancing early signs of market stabilization with significant internal and external headwinds. The company’s ability to deliver on operational improvement and platform innovation will determine whether it can offset the near-term drag from process chromatography and sustain long-term growth and margin expansion.
Industry Read-Through
Bio-Rad’s results offer a window into ongoing volatility in the life science tools and diagnostics sector. The pronounced process chromatography reset highlights the risk of revenue concentration and regulatory exposure for bioprocess suppliers, especially those over-indexed to vaccine production. Meanwhile, digital PCR’s continued adoption signals that end users are still investing in higher-value, application-specific platforms, even as capital budgets remain constrained. Diagnostics remains a relative safe haven, but growth is muted and product mix is increasingly important. Peers should heed Bio-Rad’s emphasis on operational rigor and portfolio optimization as industry-wide funding and demand headwinds persist into 2026.